GOOGL
40
-5
MAS
58
2
FTI
81
5
ROK
62
15
EL
25
4
AAP
24
6
COF
60
2
XYL
49
4
R
71
4
CMA
61
5
NWS
66
-3
LEG
36
4
PSX
47
2
XRAY
28
2
PGR
65
2
HPE
63
2
CTSH
56
2
KMB
39
2
EXC
53
-3
AON
54
2
GOOGL
40
-5
MAS
58
2
FTI
81
5
ROK
62
15
EL
25
4
AAP
24
6
COF
60
2
XYL
49
4
R
71
4
CMA
61
5
NWS
66
-3
LEG
36
4
PSX
47
2
XRAY
28
2
PGR
65
2
HPE
63
2
CTSH
56
2
KMB
39
2
EXC
53
-3
AON
54
2
Financhill
Back

InflaRx NV 10K Form

Buy
67

IFRX
InflaRx NV

Last Price:
2.10
Seasonality Move:
17.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive IFRX News And Ratings

See the #1 stock for the next 7 days that we like better than IFRX

IFRX Financial Statistics

Sales & Book Value

Annual Sales: $68.3K
Cash Flow: $-11.25M
Price / Cash Flow: 0
Annual Sales: $1.24
Price / Book: 1.68

Profitability

EPS (TTM): -1.07460
Net Income (TTM): $-61.74M
Gross Margin: $-507.93K
Return on Equity: -61.55%
Return on Assets: -53.76%

InflaRx NV Earnings Forecast

Key InflaRx NV Financial Ratios

  • The Gross Profit Margin over the past 3 years for IFRX is -743.67%.
  • The Selling, General & Administrative Expenses for IFRX have been equal to 25,554.89% of Gross Profit Margin.
  • The Research & Development expenses have been 65,026.50% of Revenue.
  • The Interest Expense is -0.08% of Operating Income.
  • The Net Earning history of IFRX is -67,631.41% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 4 years.

InflaRx NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: IFRX
CUSIP: N44821
Website: inflarx.de

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.31
Quick Ratio: 4.34

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

IFRX Technical Analysis vs Fundamental Analysis

Buy
67
InflaRx NV (IFRX) is a Buy

Is InflaRx NV a Buy or a Sell?

  • InflaRx NV stock is rated a Buy
    The current InflaRx NV [IFRX] share price is $2.08. The Score for IFRX is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.